Hobson Prior’s Post

|| Pharma Fusion Series 1.9 || 🌟 Roche partners with Ascidian Therapeutics to develop groundbreaking RNA exon editing medicines for neurological diseases. The $42 million initial payment, coupled with up to $1.8 billion in milestone payments, showcases the commitment to advancing innovative treatments. This collaboration signals a significant step forward in the pursuit of novel therapies for unmet medical needs. 💼💡 This partnership amplifies Ascidian Therapeutics pioneering RNA exon editing platform and Roche 's advanced CNS delivery technology, highlighting a transformative stride in addressing complex neurological conditions. Cheers to the collaborative efforts aiming to reshape the landscape of neurological disease treatments! 🚀 #PharmaFusion #RochePartnership #AscidianTherapeutics #RNAExonEditing #NeurologicalDiseases #MedicalAdvancements #Knowledge #niper #pharmamba

🔬🧬Imagine a world where neurodegeneration diseases like Multiple Sclerosis can be healed through alternative medicine. Such a world may not be as far off as we think with the groundbreaking work of Pheno Therapeutics Ltd. Based in Edinburgh, UK, Pheno Therapeutics has been diligently researching and developing small molecule therapeutics with the potential to revolutionize neuroprotective therapy for Multiple Sclerosis. 🌐Their novel approach uses alternative medicine to promote remyelination of damaged myelin sheaths, opening up a whole new paradigm of treatment options. 💡Want to understand more about how Pheno Therapeutics is championing this revolution in the medical field? Click on the link below to get the full scoop in our latest detailed article. https://UKT.news/?p=12825 Engage with us, share your thoughts and let's catalyze a conversation about the future of medicine. #PhenoTherapeutics #MS #Neuroprotection #AlternativeMedicine #Biotechnology #Innovation #HealthcareRevolution

📃Scientific paper: Seven Solutions for Neuroprotection in Parkinson's Disease Abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder Society Continued on ES/IODE ➡️ https://etcse.fr/FkilT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Seven Solutions for Neuroprotection in Parkinson's Disease Abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder Society Continued on ES/IODE ➡️ https://etcse.fr/FkilT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

The presentation, titled NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer's disease shows neuroprotective and neurorestorative effects , was held by Martin Jönsson, CEO at AlzeCure Pharma, and includes new preclinical data with ACD856, the lead clinical drug candidate in the NeuroRestore platform. "These new preclinical data provide further support for a potential disease-modifying effect of NeuroRestore ACD856. This, together with the previously observed memory-enhancing effects, shows a broad potential for this drug candidate," said Pontus Forsell, Head of Discovery and Research at AlzeCure Pharma. "These new results with NeuroRestore ACD856 strengthen the commercial potential of the project. The findings are not only relevant for Alzheimer's, but also for other neurodegenerative diseases, such as Parkinson's and frontal lobe dementia," said Martin Jönsson. Read more here: https://lnkd.in/dquHPmzg #alzecure #firstwordpharma #lifesciencepartnering #NeuroRestore #ADC856 #LifeScience #CEO #CTAD23

New Alzheimer's drug LM11A-31 shows promise in slowing disease progression in clinical trial n a recent study published in the journal Nature Medicine, researchers conducted a randomized, double-blinded, placebo-controlled phase 2a trial to investigate the safety and efficacy of LM11A-31 in managing Alzheimer's disease (AD) through p75 neurotrophin receptor (p75NTR) modulation. Late-onset AD is the most common form of dementia, characterized by synaptic failure, degeneration, and loss. Although two primary AD medications target the buildup of abnormal amyloid-β or tau protein, they only address a subset of the pathophysiology. Another option is to focus on deep biology, which involves receptors and signaling networks that influence fundamental biological pathways. Preclinical studies show that modulating p75NTR with the first-in-class small chemical LM11A-31 reduces amyloid-induced and pathological tau-induced synapse loss. https://lnkd.in/eYE2dTqV

📃Scientific paper: Seven Solutions for Neuroprotection in Parkinson's Disease Abstract: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder Society Continued on ES/IODE ➡️ https://etcse.fr/FkilT ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

At Mission Therapeutics, Sarah Almond and her team have found a method to help develop potential therapeutics for neurodegenerative conditions such as Parkinson’s disease. Join us for a discussion on deubiquitinating enzymes and how they may shape the future of drug development on the latest episode of Vital Science. https://okt.to/Jzh7Vd #therapeutics #neurodegenerative #Parkinsonsdisease #drugdevelopment #podcast

Cordance Medical and EXACT Therapeutics have entered a strategic partnership to pioneer a new era in drug delivery to the brain. By integrating Cordance Medical's NeuroAccess™ platform, which enables non-invasive, targeted opening of the blood-brain barrier (BBB), with EXACT Therapeutics' Acoustic Cluster Therapy (ACT®) technology, the collaboration aims to enhance the efficacy and precision of drug therapies for patients with brain diseases, including tumors and neurodegenerative disorders. This partnership promises to revolutionize treatment options, making them more effective and accessible through upcoming clinical trials. #FocusedUltrasound, #PrecisionMedicine, #BloodBrainBarrier, #alzheimers, #braintumor, #drugdelivery https://lnkd.in/gWKdRcPQ

Excited to share our new research paper on the R&D of cannabinoid therapeutics, published in Redox Biology. Our drug discovery scientists in Dr. Pam Maher's lab at Salk Institute for Biological Studies teaming up with Dr. Kim Finley's lab at San Diego State University, using FBDD and cell-based phenotypic screens, we developed novel CBN analogs with improved CNS druglikeness and neuroprotective activities. The new analogs were also proven to be efficacious in vivo for the increase in survival rates of traumatic brain injury (mTBI) in the Drosophila model. Bravo to the great research team with David Soriano Castell, Wolfgang Fischer, Alec Candib, Kim Finley, Pam Maher! Learn more: Fragment-based drug discovery and biological evaluation of novel cannabinol-based inhibitors of oxytosis/ferroptosis for neurological disorders #mitochondria #aging #neuroprotection #redox #oxytosis #ferroptosis #cannabinoid #cannabis #CBN #drugdiscovery